SL BIO
Closed (deSPAC)Health Care · biopharmaceutical company
- What it is
- A private company in health care preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Horizon Space Acquisition II Corp. (HSPT) — closed (despac), announced Jan 13, 2026.
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
The deal it’s entering
SL BIO is merging with Horizon Space Acquisition II Corp. (HSPT) currently marked Closed (deSPAC).
| Headline equity value | $5.6B |
| Post-close ticker | SLBT |
How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Was this deal done at an expensive or a cheap valuation?
SpacBrain’s read on the price
No multiple can be computed
We hold no revenue figure in US dollars for SL BIO Ltd., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $5.57bn regardless.
We have not extracted a revenue figure for this company from its filings yet. That is our gap, not a statement about the business.
Announced equity value (net debt unknown).
Not extracted from the filings yet.
Not computable — no revenue figure has been extracted from the filings yet.
No listed comparable carries a revenue multiple we can use.
What qualifies the figures above
- The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.
Common questions
Is SL BIO going public?
SL BIO has an approved merger with the SPAC Horizon Space Acquisition II Corp. (HSPT), announced Jan 13, 2026. The combined company expects to trade as SLBT. Deal status: Closed (deSPAC).
What is SL BIO's SPAC deal valuation?
The announced headline equity value is $5.6B.
Was SL BIO bought at an expensive or a cheap valuation?
We hold no revenue figure in US dollars for SL BIO Ltd., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $5.57bn regardless.
Does SL BIO have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC